Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1051 to 1065 of 1308 results for social care

  1. What interventions are effective and cost effective at raising awareness of the health risks of damp and mould in the home?

    for vulnerable groups.In the committee's experience, professionals such as care workers and health visitors, and the public, are...

  2. Skin abscess: antimicrobial prescribing

    Discontinued Reference number: GID-NG10163

  3. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).

  4. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued Reference number: GID-TA10377

  5. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer in adults.

  6. Blepharitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10168

  7. Stye: antimicrobial prescribing

    Discontinued Reference number: GID-NG10167

  8. Robot-assisted surgery for soft tissue procedures: early value assessment (HTG742)

    Early value assessment (EVA) guidance on robot-assisted surgery for soft tissue procedures.

  9. Conjunctivitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10166

  10. Erythrocyte encapsulated asparaginase for treating acute lymphoblastic leukaemia [ID864]

    Discontinued Reference number: GID-TA10047

  11. Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

    Discontinued Reference number: GID-TA10271

  12. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

  13. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    Discontinued Reference number: GID-TA10596

  14. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

  15. Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]

    Discontinued Reference number: GID-TA10202